Background: Recent-onset atrial fibrillation (AF) is a frequent cause for presentation to the emergency department. Recent studies proposed that the addition of biomarker information might improve the prediction of clinical outcomes by enabling identification of patients at high risk. Aim: We aimed to examine the role of cardiac troponin I as a predictor of clinical outcome in patients with first episode acute AF. Design: Patients, 18 years or older, presenting to our hospital with a primary diagnosis of first episode acute AF were included in this retrospective study. Methods: The association between elevated cTnI with mortality or the composite endpoint (mortality, stroke or heart failure) was examined in a univariate Cox regression model. Results: Of the 274 study patients, 111 had elevated cTnI levels (41%). Increased cTnI was associated with older age, history of myocardial infarction, higher creatinine levels and higher heart rate (All P < 0.01). Elevated cTn was associated with an adjusted hazard ratio of 1.86 [95% confidence interval (CI) 1.17-2.96; P ¼ 0.009] for mortality and 1.89 (95% CI 1.27-2.84; P ¼ 0.002) for the combined endpoint. Conclusions: Elevated cardiac Troponin I is a significant predictor of mortality and a composite endpoint of mortality, stroke or heart failure in patients presenting with first episode acute AF.
Introduction
Recent-onset atrial fibrillation (AF) is a frequent cause for presentation to the emergency department. 1, 2 Patients presenting to the emergency department with AF may have a transient benign condition but may also develop complications such as worsening heart failure, angina and hemodynamic decompensation.
Recent studies proposed that the addition of biomarker information (i.e. troponin and natriuretic peptides) might improve the prediction of clinical outcomes by enabling identification of patients at high risk. 3 The independent prognostic value of elevated cardiac troponin (cTn) has also been validated by similar findings in healthy elderly subjects, patients with acute and chronic atherosclerotic diseases, and patients with congestive heart failure. [4] [5] [6] [7] Received: 21 September 2016; Revised (in revised form): 31 January 2017 Two recent large-scale trials have shown an incremental prognostic value of hs-TnI and hs-TnT levels for stroke, cardiac and total death, other ischemic events and major bleeding in patients with AF. 3, 8 However, these results were obtained in ambulatory patients, many of whom had permanent or persistent atrial fibrillation.
The aim of the current study is to examine the role and performance of cardiac troponin I (cTn I) as a predictor of clinical outcome in patients admitted for first episode AF.
Methods
Patients, 18 years or older, who presented to Rambam Health Care Campus between 1 January 2007 and 31 November 2011 with a primary diagnosis of first episode acute AF were included in this retrospective study. The ethics committee of Rambam Health Care Campus reviewed and approved the study (#0514-12-RBM). The need for written informed consent was specifically waived for the following reasons: this was a retrospective study that cannot influence patient treatments or outcomes, exclusively based on data extraction from medical chart records, and it would not be feasible to get patient's consent for access to all charts. The data were analyzed anonymously.
The diagnosis of AF was made when the 12-lead ECG demonstrated replacement of regular P-waves by an undulating baseline and irregular ventricular complexes. A detailed review of patients' medical history was done to rule out previous documentation of AF.
Before 1 December 2011 cTnI levels were considered elevated if the value was >0.2 ng/ml, but cut-off levels were revised on 1 December 2011, and since then values above 0.028 ng/ml are considered elevated. Patients with cTnI above 1 ng/ml were excluded when they were suspected as having acute myocardial infarction according to the patient's medical history, physical examination and electrocardiographic findings. Patients with cTnI values 2 ng/ml were excluded, as they were more likely to represent acute myocardial infarction rather than secondary myocardial ischemia.
Patients' demographics, medical history, permanent medications, laboratory studies, electrocardiographic and echocardiographic reports were collected from the computed medical registry. Mortality data were retrieved from the databases of our hospital and the Ministry of Health. Exclusion criteria included age under 18 years, previous documentation of AF and AF secondary to acute medical illness.
Demographic data included age, gender, date of birth and cultural background (Jewish or Arab).
Data regarding the following medical conditions were retrieved from the patients' medical records: myocardial infarction (MI), congestive heart failure (CHF), peripheral vascular disease (PVD), cerebrovascular attack (CVA), hemiplegia, dementia, chronic obstructive pulmonary disease (COPD), connective tissue disease (CTD), gastric or duodenal ulcer, acquired immune-deficiency virus (AIDS), diabetes mellitus (DM) with and without end organ damage, leukemia, lymphoma, myeloma, solid tumors, metastatic solid tumors, renal failure and hepatic disease. Permanent medications were recorded at admission and the time of discharge and included the following: aspirin, Clopidogrel, Ticagrelor, Prasugrel, Warfarin, Enoxaparin, Dabigtran, Rivaruxaban, statins, beta-blockers, Angiotensin converting enzyme inhibitors (ACE-I), Angiotensin receptor blockers (ARB'S), calcium channel blockers (CCB), Spiranolactone, Furosemide, thiazides, nitrates, Amiodarone, Dronedarone, Flecanide and Sotalol. The echocardiographic parameters collected included: systolic and diastolic dysfunctions, ejection fraction (EF), left atrium diameter, left ventricle end-diastolic diameter (LVEDD), left ventricular hypertrophy (LVH), presence of thrombus or significant echocardiographic contrast (SEC) in left atrium or appendage, mitral stenosis (MS) and mitral regurgitation (MR) and the degree of severity, aortic stenosis (AS) and aortic regurgitation (AR) and its severity, tricuspid stenosis (TS) and tricuspid regurgitation (TR) and its severity, the presence of pulmonary hypertension (PHTN) and degree of severity, aortic diameter and the presence of simple or complex aortic plaques. Electrocardiographic parameters collected upon admission and at the time of discharge were: rhythm at discharge, rate, ST-segment abnormalities, T-wave changes, the presence of wide QRS complex and prolonged corrected QT interval, the presence of left anterior or left posterior hemi-blocks, and right or left bundle branch block.
The following laboratory variables on admission were collected: white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin (HGB) levels, mean corpuscular volume (MCV), RBC distribution and width (RDW), sodium, potassium, creatinine, blood urea nitrogen (BUN), glucose, calcium, phosphorus, albumin, creatine phosphokinase (CPK), uric acid, low density protein (LDL), troponin, prothrombin time (PT), partial thromboplasin time (PTT), international normalized ratio (INR), thyroidstimulating hormone (TSH), free T4 (FT4) and free T3 (FT3).
Complete blood counts (CBC) were performed using the XE 2100, XT 4000 (Sysmex, Europe GmbH, Nordestedt, Germany). Coagulation profiles were performed using the Sysmex CA-7000 (Siemens Healthcare Diagnostics, Marburg, Germany). Glucose, BUN, creatinine, sodium, potassium, calcium, phosphorus, albumin, CPK, uric acid and LDL levels were measured using the 'Dimension' (Siemens Healthcare Diagnostics Deerfield, Illinois, USA). Cardiac troponin levels before 1.2.2011 were measured using the AXYM, Abbott, and after the 1.2.2011 using the Architect, Abbott.
Statistical analysis
Data are expressed as mean 6 SD for clinical characteristics and median with 25th and 75th percentiles. The baseline characteristics of the groups were compared using unpaired t-tests for continuous variables (or by the nonparametric Mann-Whitney Rank Sum test) and by the v 2 statistic for categorical variables.
The association of clinical variables and cTnI elevation were assessed using a logistic regression model. Event-free survival was estimated by the Kaplan-Meier method, and curves were compared with the log-rank test. Stepwise Cox proportional hazards models with backward selection were used to determine which variables were significantly related to the primary or secondary endpoints. Variables associated with mortality or the composite endpoint in the univariate Cox regression analysis (Wald test; P < 0.10) were used in the multivariable Cox model. The following baseline clinical characteristics were considered in the multivariate procedure: age, gender, hypertension, DM, Charlson score, history of myocardial infarction, CVA, and heart failure, peripheral vascular disease, serum creatinine and elevated cTnI level.
Differences were considered statistically significant at the two-sided P < 0.05 level. Statistical analyses were performed using the STATA version 13.1 (College station, TX, USA).
Results
The cohort included 274 patients who were diagnosed with first episode acute AF. These patients were divided into two groups on the basis of normal or elevated cardiac troponin I (cTnI). One hundred and sixty three patients had normal cTnI levels on admission, while 111 had elevated cTnI levels. Baseline clinical characteristics of the patients are presented in Table 1 . The group of patients with elevated cTnI were older, had larger percentage of hypertension, had higher Charlson score, more congestive heart failure and prior CVA or TIA, higher creatinine levels, lower hemoglobin levels, and higher CHA 2 DS 2 -VASc and CHADS scores.
Several parameters in our cohort were associated with elevated cTnI. Age >75, previous myocardial infarction, increased creatinine levels and heart rate >122/min were all associated with elevated cTnI (Table 2) .
Predictors of mortality
During a mean follow up time was 35 months, 82 deaths occurred, with 51 and 31 events in patients with and without elevated cTn, respectively. In the univariate analysis, several factors were associated with mortality in patients presenting with acute AF (Table 3) . After adjustment for age, gender, diabetes, hypertension, heart rate, the following variables were significantly associated with mortality in the multivariable analysis: Age > 75 years, heart failure, Charlson score, hemoglobin level and elevated cardiac troponin I.
Predictors of composite endpoint for mortality, stroke or heart failure
The Kaplan-Meier curve demonstrates that the composite endpoint is increased among patients with elevated cTnI is when compared with patients with normal cTnI. It is worthwhile to note that the two groups of patients separated early during the follow up with regard to the composite endpoint (Figure 1) .
In the univariate analysis, several factors were associated with the composite endpoint in patients presenting with acute AF (Table 4) . After adjustment for age, gender, diabetes, hypertension, heart rate, the following variables were significantly associated with the composite endpoint in the multivariable analysis: Age > 75 years, heart failure, Charlson score, hemoglobin level and elevated cardiac troponin I.
Predictive value of elevated cTnI over the CHA 2 DS 2 -VASc score
We also tested the association the incremental prognostic value of cTnI over the CHA 2 DS 2 -VASc score with regard to mortality. The CHA 2 DS 2 -VASc score was significantly related to mortality with a HR of 1.44 for each point (95% CI 1.28-1.61, P < 0.0001). Elevated cTn remained significantly associated with mortality when added to the model containing the CHA 2 DS 2 -VASc score 
Discussion
Our study demonstrated that cTnI at admission is a significant predictor of mortality in patients presenting with first episode acute AF. Even after excluding patients with high levels of cTnI, mildly elevated cTnI levels were still associated with increased mortality, compared to patients with normal cTnI levels. Atrial fibrillation is the most common sustained cardiac arrhythmia and its prevalence increases with the aging of the population. 9 It contributes significantly to population morbidity and mortality, and presently available therapeutic approaches have major limitations, including limited efficacy and potentially serious side effects. 10 Stroke and heart failure along with anticoagulation related major bleeding are among the most serious comorbidities of AF. While paroxysmal, persistent or permanent AF may represent medical conditions that might predispose the patient to increased mortality risk, patients with their first episode of AF may or may not have this association with increased mortality. In our study we aimed to understand what clinical and laboratory parameters might predict increased mortality in this class of patients. In addition to cTnI, age over 75 years old, increased Charlson score, heart failure, increased creatinine levels and lower hemoglobin levels were associated with increased mortality in these unique patients.
While it seems logical that optimally treating modifiable risk factors like heart failure and low hemoglobin levels would decrease mortality risk, this might not be the issue with elevated cTnI, especially when acute myocardial infarction is not the cause of AF.
Hijazi et al, in their sub-study of the ARISTOTLE study, found that elevated cTnI and cTnT were associated with increased risk for stroke, systemic embolism, myocardial infarction and cardiac death. 8 Unlike in our study, the patients in the ARISTOTLE study already had documented AF and at least one risk factor for stroke.
In the biomarker substudy of the ENGAGE AF-TIMI 48 trial, cTnI, N-terminal pro-B-type natriuretic peptide, and D-dimer were associated with an approximately three-fold to four-fold gradient of risk for stroke, systemic embolic events, or death across groups of increasing biomarker concentration after adjustment for the CHA 2 DS 2 -VASc score.
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In another study from Hijazi and colleagues, in their subanalysis study of the RELY trial, they showed that persistent elevation in cardiac troponin, compared with transient elevation, was associated with higher risk of cardiovascular events and mortality. 12 Here again, patients in the RELY study had documented AF and other risk factors such as stroke and congestive heart failure. Gupta et al. have shown that even mildly elevated troponin levels in patients presenting to the emergency room with primary diagnosis of AF are associated with increased incidence of coronary artery disease and 1 year mortality. 13 In contrast to patients in our study, they may have had documented AF and were not necessarily experiencing their first episode of AF.
Conti and colleagues have shown that even minimal or minor elevations in cTnI were associated with a high risk for short term (1 month) composite outcome (stroke, acute coronary syndrome, revascularization and death) but less so or not at all for the long term (one year) in patients presenting to the ER with acute AF of less than 48 h. 14 Although it has been reported that AF itself may cause cardiac troponin elevations with no evidence of significant coronary artery disease on catheterization, 15 several studies have
shown that mild elevation in cardiac troponin in the setting of AF and the absence of evident coronary artery disease, may actually represent masked critical coronary disease that might contribute to increased mortality in these patients, which can be identified and properly treated aiming to reduce the risk of mortality in this subset of patients. 16 Interestingly, Ulimoen et al. 17 have shown that rate-reducing treatments in patients with AF significantly reduced the levels of cTnT, but unfortunately, they did not examine the effect of this reduction on the clinical outcomes of mortality or stroke in these patients. In addition to its association with mortality in our study, cTnI was also associated with the composite endpoint for mortality, stroke or heart failure. The finding that cTnI may predict the development of heart failure in patients with first episode of acute AF, together with the reported data that elevated cTnI in patients with AF may represent masked coronary artery disease, make echocardiographic examinations reasonable in this group of patients. Apart from the commonly used and accepted methods for assessing the risk for stroke in patients with AF, namely CHADS2 and CHA2DS2-VASc scores, we have shown that cTnI, along with other variables (Charlson score and hemoglobin levels) is a predictor for the future development of stroke. Whether cTnI should be considered a risk factor for the development of stroke, is an issue that warrants further prospective examination.
Our study has several limitations. The first and most important is the retrospective nature of the study. The relatively small number of patients is the second limitation. The third is that we considered only cTnI but not cTnT which might have an added value. The fourth limitation of the study is the paucity of data regarding the exact cause of mortality. We also did not make the distinction between ischemic versus hemorrhagic stroke and did not relate to the severity of congestive heart failure, which at some point might turn out to be a strength.
In conclusion, our study has shown that cTnI is a significant predictor of mortality and a composite endpoint of mortality, stroke or heart failure in patients presenting with the first episode of acute AF. Further prospective studies are needed to define the exact role of cTnI in this unique setting and whether it should imply a thorough workup for hidden coronary artery or other cardiac disease.
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